peter attia on semaglutide A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Peter Attia on X: "This

FEBS Letters 1988;238:343 Pickart L et al

& Pastor, R

Notably, participants had not reached a weight loss plateau by the end of the 48-week study, suggesting that the full weight loss potential of retatrutide may extend beyond this timeframe

Secondly, GLP-1 reduces the liver's glucose production, further aiding in blood sugar control

Why Regulatory Compliance Matters Strong compliance programs help organizations: Reduce enforcement risks Improve inspection readiness Strengthen patient safety protections Support business continuity Protect brand reputation Minimize legal exposure Organizations that proactively address regulatory concerns are generally better positioned for sustainable growth